Dan O’Connor, President, Director and Chief Executive Officer of OncoSec discusses the KEYNOTE-695 Study of TAVO + Keytruda in refractory metastatic melanoma.

In this video, Mr. O’Connor provides an update regarding tumor responses in its KEYNOTE-695 global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO (tavokinogene telseplasmid / IL-12) with intravenous Keytruda (pembrolizumab) in patients with unresectable, advanced melanoma.